Generali Asset Management SPA SGR Makes New $1.18 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Generali Asset Management SPA SGR bought a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 15,111 shares of the medical device company's stock, valued at approximately $1,175,000.

A number of other hedge funds have also recently bought and sold shares of DXCM. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter worth about $25,000. Private Trust Co. NA boosted its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares in the last quarter. Heck Capital Advisors LLC bought a new position in shares of DexCom during the 4th quarter valued at about $38,000. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of DexCom during the 4th quarter valued at $49,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and increased their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Wells Fargo & Company reissued an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup lifted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $99.82.

Remove Ads

DexCom Stock Down 2.3 %

NASDAQ DXCM traded down $1.77 during trading hours on Tuesday, hitting $73.55. The company's stock had a trading volume of 3,240,370 shares, compared to its average volume of 3,915,036. The company's 50-day simple moving average is $83.24 and its two-hundred day simple moving average is $77.07. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $28.74 billion, a PE ratio of 51.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.